 Rasika Mathias
Concepts (799)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 93 | 2026 | 1430 | 5.190 |
Why?
| | Polymorphism, Single Nucleotide | 105 | 2026 | 2181 | 4.540 |
Why?
| | Genetic Predisposition to Disease | 71 | 2026 | 2399 | 4.030 |
Why?
| | Peanut Hypersensitivity | 7 | 2026 | 143 | 3.670 |
Why?
| | Asthma | 51 | 2025 | 1797 | 3.540 |
Why?
| | Arachis | 6 | 2026 | 108 | 2.580 |
Why?
| | Whole Genome Sequencing | 28 | 2026 | 178 | 2.320 |
Why?
| | Dermatitis, Atopic | 9 | 2023 | 322 | 2.180 |
Why?
| | Precision Medicine | 22 | 2026 | 461 | 2.080 |
Why?
| | Food Hypersensitivity | 4 | 2023 | 164 | 1.970 |
Why?
| | Genetic Variation | 31 | 2025 | 976 | 1.970 |
Why?
| | Fatty Acid Desaturases | 12 | 2021 | 31 | 1.880 |
Why?
| | Genome, Human | 20 | 2025 | 422 | 1.770 |
Why?
| | Immunoglobulin E | 18 | 2021 | 315 | 1.730 |
Why?
| | Platelet Aggregation | 12 | 2021 | 99 | 1.660 |
Why?
| | Genotype | 42 | 2025 | 1857 | 1.580 |
Why?
| | Induced Pluripotent Stem Cells | 4 | 2021 | 273 | 1.570 |
Why?
| | Allergens | 6 | 2026 | 386 | 1.560 |
Why?
| | Exome | 14 | 2022 | 229 | 1.530 |
Why?
| | Genomics | 18 | 2025 | 831 | 1.480 |
Why?
| | Multifactorial Inheritance | 6 | 2025 | 209 | 1.470 |
Why?
| | Immunoglobulin G | 4 | 2026 | 892 | 1.460 |
Why?
| | Blood Platelets | 12 | 2022 | 379 | 1.410 |
Why?
| | Kaposi Varicelliform Eruption | 4 | 2021 | 21 | 1.330 |
Why?
| | Alleles | 22 | 2023 | 896 | 1.330 |
Why?
| | Quantitative Trait Loci | 19 | 2026 | 381 | 1.320 |
Why?
| | Genetics, Population | 16 | 2025 | 217 | 1.280 |
Why?
| | Megakaryocytes | 3 | 2021 | 34 | 1.210 |
Why?
| | Phenotype | 51 | 2025 | 3170 | 1.180 |
Why?
| | Humans | 250 | 2026 | 145750 | 1.150 |
Why?
| | Genetic Loci | 18 | 2021 | 267 | 1.130 |
Why?
| | Fatty Acids, Omega-6 | 5 | 2017 | 47 | 1.110 |
Why?
| | Nasal Mucosa | 3 | 2025 | 112 | 1.040 |
Why?
| | Multigene Family | 9 | 2021 | 210 | 1.000 |
Why?
| | Coronary Artery Disease | 11 | 2025 | 750 | 0.980 |
Why?
| | DNA Methylation | 7 | 2025 | 690 | 0.950 |
Why?
| | Receptors, Cell Surface | 8 | 2024 | 372 | 0.940 |
Why?
| | Transcriptome | 5 | 2025 | 1043 | 0.940 |
Why?
| | Gene Frequency | 23 | 2024 | 489 | 0.910 |
Why?
| | Gene Expression Regulation | 11 | 2025 | 2601 | 0.910 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 13 | 2026 | 103 | 0.900 |
Why?
| | Linoleic Acid | 6 | 2023 | 44 | 0.850 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2024 | 25 | 0.830 |
Why?
| | Hypersensitivity, Immediate | 2 | 2023 | 41 | 0.800 |
Why?
| | Models, Genetic | 14 | 2025 | 527 | 0.780 |
Why?
| | Male | 119 | 2026 | 72992 | 0.770 |
Why?
| | Genetic Linkage | 14 | 2022 | 273 | 0.770 |
Why?
| | HLA-DQ alpha-Chains | 2 | 2022 | 17 | 0.740 |
Why?
| | Female | 119 | 2026 | 79025 | 0.720 |
Why?
| | Chromosome Mapping | 16 | 2021 | 507 | 0.720 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 11 | 2021 | 920 | 0.700 |
Why?
| | 2S Albumins, Plant | 1 | 2022 | 31 | 0.690 |
Why?
| | Gene Expression | 4 | 2025 | 1478 | 0.690 |
Why?
| | Gene-Environment Interaction | 4 | 2026 | 180 | 0.690 |
Why?
| | Linkage Disequilibrium | 19 | 2022 | 255 | 0.690 |
Why?
| | Mosaicism | 4 | 2025 | 73 | 0.680 |
Why?
| | Antigens, Plant | 1 | 2022 | 55 | 0.680 |
Why?
| | Nucleotide Transport Proteins | 1 | 2021 | 1 | 0.680 |
Why?
| | High-Throughput Nucleotide Sequencing | 6 | 2019 | 534 | 0.680 |
Why?
| | Frailty | 4 | 2025 | 205 | 0.670 |
Why?
| | Middle Aged | 71 | 2026 | 36297 | 0.660 |
Why?
| | Antibody Formation | 1 | 2022 | 288 | 0.640 |
Why?
| | von Willebrand Factor | 6 | 2025 | 85 | 0.640 |
Why?
| | Platelet Function Tests | 3 | 2021 | 35 | 0.620 |
Why?
| | Herpesvirus 1, Human | 1 | 2021 | 84 | 0.620 |
Why?
| | Genetic Association Studies | 13 | 2024 | 371 | 0.610 |
Why?
| | Lung | 10 | 2022 | 4116 | 0.600 |
Why?
| | Lipids | 8 | 2023 | 707 | 0.590 |
Why?
| | Pedigree | 8 | 2025 | 515 | 0.580 |
Why?
| | Adult | 68 | 2025 | 40867 | 0.570 |
Why?
| | Open Reading Frames | 3 | 2021 | 130 | 0.560 |
Why?
| | Fibrinogen | 7 | 2024 | 180 | 0.540 |
Why?
| | Diabetes Mellitus, Type 2 | 11 | 2026 | 2602 | 0.530 |
Why?
| | Alzheimer Disease | 1 | 2023 | 630 | 0.500 |
Why?
| | Chromosomes, Human, Pair 11 | 5 | 2014 | 59 | 0.490 |
Why?
| | Human Migration | 1 | 2016 | 25 | 0.490 |
Why?
| | Computational Biology | 5 | 2025 | 669 | 0.490 |
Why?
| | Pulmonary Emphysema | 3 | 2014 | 277 | 0.480 |
Why?
| | Case-Control Studies | 21 | 2025 | 3634 | 0.480 |
Why?
| | Risk Factors | 24 | 2025 | 10916 | 0.470 |
Why?
| | Platelet Activation | 4 | 2018 | 99 | 0.470 |
Why?
| | Gene Flow | 1 | 2016 | 87 | 0.460 |
Why?
| | Evolution, Molecular | 3 | 2019 | 494 | 0.450 |
Why?
| | Software | 5 | 2024 | 680 | 0.440 |
Why?
| | Haplotypes | 14 | 2025 | 500 | 0.430 |
Why?
| | Blood Proteins | 3 | 2025 | 239 | 0.420 |
Why?
| | Geography | 2 | 2016 | 187 | 0.420 |
Why?
| | RNA | 1 | 2021 | 912 | 0.420 |
Why?
| | Polymorphism, Genetic | 11 | 2017 | 615 | 0.410 |
Why?
| | Aging | 5 | 2025 | 1973 | 0.410 |
Why?
| | HLA-B7 Antigen | 1 | 2013 | 7 | 0.400 |
Why?
| | Fatty Acids, Unsaturated | 4 | 2020 | 96 | 0.400 |
Why?
| | Diet | 4 | 2023 | 1278 | 0.400 |
Why?
| | Desensitization, Immunologic | 2 | 2026 | 89 | 0.400 |
Why?
| | Biomarkers | 8 | 2025 | 4302 | 0.390 |
Why?
| | Bronchial Hyperreactivity | 1 | 2014 | 104 | 0.390 |
Why?
| | Epigenesis, Genetic | 6 | 2024 | 693 | 0.380 |
Why?
| | Quantitative Trait, Heritable | 6 | 2021 | 114 | 0.380 |
Why?
| | Interferon-gamma | 3 | 2015 | 784 | 0.380 |
Why?
| | Hypersensitivity | 4 | 2024 | 254 | 0.370 |
Why?
| | Mutation | 10 | 2026 | 4090 | 0.370 |
Why?
| | Airway Obstruction | 1 | 2014 | 153 | 0.360 |
Why?
| | Child | 30 | 2025 | 22738 | 0.350 |
Why?
| | Immunity, Cellular | 1 | 2013 | 274 | 0.350 |
Why?
| | Fatty Acids, Omega-3 | 3 | 2021 | 143 | 0.350 |
Why?
| | Chromosome Aberrations | 3 | 2026 | 166 | 0.340 |
Why?
| | Leukocytes | 4 | 2023 | 296 | 0.330 |
Why?
| | Likelihood Functions | 5 | 2012 | 138 | 0.330 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2011 | 66 | 0.330 |
Why?
| | Cardiovascular Diseases | 8 | 2025 | 2190 | 0.330 |
Why?
| | United States | 30 | 2026 | 16122 | 0.330 |
Why?
| | Mendelian Randomization Analysis | 3 | 2024 | 58 | 0.330 |
Why?
| | Dyslipidemias | 3 | 2016 | 184 | 0.330 |
Why?
| | Aged | 35 | 2025 | 26212 | 0.320 |
Why?
| | RNA, Long Noncoding | 2 | 2023 | 172 | 0.310 |
Why?
| | DNA, Mitochondrial | 2 | 2023 | 211 | 0.310 |
Why?
| | Liver | 7 | 2024 | 1899 | 0.310 |
Why?
| | Diabetes Mellitus | 4 | 2023 | 1101 | 0.310 |
Why?
| | Cell Adhesion Molecules | 2 | 2024 | 181 | 0.310 |
Why?
| | Genome | 4 | 2022 | 305 | 0.310 |
Why?
| | Factor VIII | 2 | 2024 | 106 | 0.300 |
Why?
| | Cohort Studies | 15 | 2021 | 6032 | 0.300 |
Why?
| | Adolescent | 29 | 2023 | 22569 | 0.300 |
Why?
| | Telomere | 5 | 2024 | 287 | 0.300 |
Why?
| | Computer Simulation | 8 | 2024 | 1003 | 0.290 |
Why?
| | Organ Specificity | 2 | 2021 | 309 | 0.290 |
Why?
| | Smoking | 6 | 2018 | 1477 | 0.280 |
Why?
| | Healthcare Disparities | 3 | 2025 | 736 | 0.280 |
Why?
| | Pharmacogenetics | 2 | 2020 | 175 | 0.280 |
Why?
| | Genetic Pleiotropy | 3 | 2019 | 30 | 0.280 |
Why?
| | Adaptation, Physiological | 1 | 2012 | 560 | 0.270 |
Why?
| | Dietary Fats | 1 | 2010 | 308 | 0.270 |
Why?
| | Germ-Line Mutation | 3 | 2025 | 177 | 0.270 |
Why?
| | HLA-DQ beta-Chains | 2 | 2021 | 58 | 0.260 |
Why?
| | Atherosclerosis | 2 | 2025 | 409 | 0.260 |
Why?
| | Arachidonic Acid | 6 | 2015 | 102 | 0.260 |
Why?
| | Point Mutation | 2 | 2025 | 241 | 0.260 |
Why?
| | Gene Regulatory Networks | 2 | 2024 | 319 | 0.260 |
Why?
| | Fasting | 2 | 2022 | 279 | 0.260 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 923 | 0.250 |
Why?
| | Blood Glucose | 5 | 2026 | 2344 | 0.250 |
Why?
| | Body Height | 4 | 2015 | 203 | 0.250 |
Why?
| | Loss of Function Mutation | 3 | 2021 | 45 | 0.250 |
Why?
| | Restless Legs Syndrome | 1 | 2006 | 20 | 0.240 |
Why?
| | Aspirin | 4 | 2018 | 406 | 0.240 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2006 | 24 | 0.240 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2006 | 60 | 0.240 |
Why?
| | Computer Graphics | 1 | 2006 | 41 | 0.240 |
Why?
| | Schistosoma japonicum | 2 | 2017 | 34 | 0.230 |
Why?
| | Lipoprotein Lipase | 1 | 2006 | 56 | 0.230 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2017 | 751 | 0.230 |
Why?
| | Metabolic Syndrome | 4 | 2025 | 361 | 0.230 |
Why?
| | Biological Specimen Banks | 3 | 2024 | 118 | 0.230 |
Why?
| | Health Status Disparities | 3 | 2025 | 321 | 0.220 |
Why?
| | Serine | 1 | 2006 | 143 | 0.220 |
Why?
| | Helminthiasis | 2 | 2017 | 11 | 0.220 |
Why?
| | Endophenotypes | 1 | 2025 | 23 | 0.220 |
Why?
| | Genomic Structural Variation | 1 | 2025 | 13 | 0.220 |
Why?
| | von Willebrand Diseases | 1 | 2025 | 28 | 0.220 |
Why?
| | Hematopoietic Stem Cells | 3 | 2024 | 435 | 0.220 |
Why?
| | Hematopoiesis | 2 | 2023 | 193 | 0.220 |
Why?
| | Membrane Proteins | 7 | 2017 | 1166 | 0.220 |
Why?
| | Chromosomes, Human, Y | 1 | 2025 | 37 | 0.220 |
Why?
| | Models, Statistical | 7 | 2021 | 672 | 0.220 |
Why?
| | Cholesterol, HDL | 4 | 2016 | 201 | 0.220 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2025 | 34 | 0.220 |
Why?
| | Consanguinity | 2 | 2005 | 49 | 0.210 |
Why?
| | Child, Preschool | 17 | 2026 | 11866 | 0.210 |
Why?
| | Chromosome Deletion | 1 | 2025 | 126 | 0.210 |
Why?
| | Kininogens | 1 | 2024 | 6 | 0.210 |
Why?
| | Inflammation | 6 | 2024 | 2883 | 0.210 |
Why?
| | Chromosomes, Human, Pair 16 | 3 | 2021 | 36 | 0.210 |
Why?
| | Lectins, C-Type | 1 | 2024 | 59 | 0.210 |
Why?
| | Interleukin-13 | 3 | 2023 | 146 | 0.210 |
Why?
| | Forced Expiratory Volume | 4 | 2019 | 450 | 0.200 |
Why?
| | Young Adult | 13 | 2022 | 14250 | 0.200 |
Why?
| | Telomere Homeostasis | 1 | 2024 | 33 | 0.200 |
Why?
| | Chemokines, CC | 2 | 2014 | 33 | 0.200 |
Why?
| | Blood Pressure | 6 | 2022 | 1782 | 0.200 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2770 | 0.200 |
Why?
| | Liver Cirrhosis | 2 | 2017 | 287 | 0.200 |
Why?
| | Leukemia | 1 | 2026 | 246 | 0.200 |
Why?
| | Population Groups | 3 | 2019 | 56 | 0.200 |
Why?
| | Fibronectins | 1 | 2024 | 136 | 0.200 |
Why?
| | Menopause, Premature | 1 | 2023 | 12 | 0.200 |
Why?
| | Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 2 | 2022 | 3 | 0.200 |
Why?
| | Barbados | 8 | 2013 | 8 | 0.190 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 2 | 2017 | 31 | 0.190 |
Why?
| | Administration, Oral | 1 | 2026 | 867 | 0.190 |
Why?
| | Respiration | 2 | 2014 | 207 | 0.190 |
Why?
| | Blood Cells | 1 | 2022 | 38 | 0.190 |
Why?
| | Proteomics | 3 | 2024 | 1188 | 0.190 |
Why?
| | Frameshift Mutation | 1 | 2022 | 31 | 0.190 |
Why?
| | Erythrocytes | 2 | 2021 | 749 | 0.190 |
Why?
| | Interleukin-4 | 2 | 2023 | 207 | 0.190 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 2025 | 92 | 0.180 |
Why?
| | Chromosomes, Human, X | 2 | 2021 | 77 | 0.180 |
Why?
| | Promoter Regions, Genetic | 6 | 2023 | 1247 | 0.180 |
Why?
| | Telomere Shortening | 1 | 2022 | 19 | 0.180 |
Why?
| | Eczema | 1 | 2023 | 66 | 0.180 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 362 | 0.180 |
Why?
| | Proteome | 2 | 2024 | 514 | 0.180 |
Why?
| | Nerve Tissue Proteins | 5 | 2022 | 592 | 0.180 |
Why?
| | Acute Coronary Syndrome | 2 | 2016 | 297 | 0.180 |
Why?
| | Gastritis | 1 | 2023 | 117 | 0.180 |
Why?
| | Coronary Disease | 2 | 2019 | 382 | 0.170 |
Why?
| | Genetic Heterogeneity | 3 | 2016 | 66 | 0.170 |
Why?
| | Enteritis | 1 | 2023 | 105 | 0.170 |
Why?
| | HLA-A2 Antigen | 1 | 2021 | 36 | 0.170 |
Why?
| | Pseudomonas Infections | 2 | 2015 | 230 | 0.170 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2025 | 1146 | 0.170 |
Why?
| | Dinoprostone | 1 | 2022 | 180 | 0.170 |
Why?
| | Patient Compliance | 1 | 2025 | 588 | 0.170 |
Why?
| | Americas | 1 | 2021 | 27 | 0.170 |
Why?
| | Spain | 1 | 2021 | 50 | 0.170 |
Why?
| | Infant | 10 | 2026 | 10089 | 0.170 |
Why?
| | DNA Copy Number Variations | 2 | 2020 | 188 | 0.170 |
Why?
| | Cyclooxygenase Inhibitors | 2 | 2014 | 82 | 0.170 |
Why?
| | Pulmonary Medicine | 2 | 2019 | 78 | 0.170 |
Why?
| | Peru | 1 | 2021 | 60 | 0.170 |
Why?
| | Gene Ontology | 1 | 2021 | 54 | 0.170 |
Why?
| | Leishmaniasis, Visceral | 1 | 2001 | 24 | 0.170 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2021 | 85 | 0.170 |
Why?
| | Cytokines | 4 | 2023 | 2069 | 0.160 |
Why?
| | Glutathione Transferase | 1 | 2021 | 92 | 0.160 |
Why?
| | Odds Ratio | 7 | 2019 | 1083 | 0.160 |
Why?
| | Risk | 7 | 2019 | 923 | 0.160 |
Why?
| | DNA-Binding Proteins | 4 | 2023 | 1482 | 0.160 |
Why?
| | gamma-Linolenic Acid | 1 | 2020 | 2 | 0.160 |
Why?
| | Social Determinants of Health | 1 | 2025 | 309 | 0.160 |
Why?
| | Receptors, Nicotinic | 2 | 2013 | 327 | 0.160 |
Why?
| | HLA-DQ Antigens | 1 | 2021 | 174 | 0.160 |
Why?
| | Chromosomes, Human, Pair 19 | 3 | 2012 | 27 | 0.160 |
Why?
| | Lipid Metabolism | 2 | 2021 | 529 | 0.160 |
Why?
| | Soybean Oil | 1 | 2020 | 15 | 0.160 |
Why?
| | Immunologic Factors | 1 | 2022 | 260 | 0.160 |
Why?
| | Algorithms | 7 | 2025 | 1850 | 0.160 |
Why?
| | Plant Oils | 1 | 2020 | 33 | 0.160 |
Why?
| | Amish | 1 | 2020 | 7 | 0.160 |
Why?
| | Base Sequence | 4 | 2021 | 2171 | 0.160 |
Why?
| | Energy Intake | 1 | 2023 | 512 | 0.160 |
Why?
| | beta-Globins | 1 | 2019 | 8 | 0.160 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2018 | 499 | 0.150 |
Why?
| | Cholesterol, LDL | 5 | 2022 | 360 | 0.150 |
Why?
| | Hemorrhage | 1 | 2025 | 822 | 0.150 |
Why?
| | Thrombosis | 5 | 2024 | 400 | 0.150 |
Why?
| | Occipital Lobe | 1 | 2019 | 26 | 0.150 |
Why?
| | Genomic Instability | 1 | 2020 | 68 | 0.150 |
Why?
| | Homozygote | 3 | 2016 | 199 | 0.150 |
Why?
| | Mutation, Missense | 2 | 2023 | 335 | 0.150 |
Why?
| | 8,11,14-Eicosatrienoic Acid | 3 | 2020 | 6 | 0.150 |
Why?
| | Th2 Cells | 4 | 2023 | 175 | 0.150 |
Why?
| | HLA-DRB1 Chains | 1 | 2020 | 110 | 0.150 |
Why?
| | Parietal Lobe | 1 | 2019 | 61 | 0.150 |
Why?
| | Eicosanoids | 2 | 2022 | 58 | 0.150 |
Why?
| | Photometry | 1 | 2019 | 3 | 0.150 |
Why?
| | Tissue Plasminogen Activator | 1 | 2021 | 248 | 0.150 |
Why?
| | Chromosomes, Human, Pair 12 | 4 | 2019 | 22 | 0.150 |
Why?
| | Diabetic Nephropathies | 1 | 2023 | 322 | 0.150 |
Why?
| | Genes, Mitochondrial | 1 | 2018 | 13 | 0.140 |
Why?
| | Chromatography, Gas | 1 | 2019 | 30 | 0.140 |
Why?
| | Sleep Medicine Specialty | 1 | 2019 | 10 | 0.140 |
Why?
| | Flame Retardants | 1 | 2019 | 10 | 0.140 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2025 | 47 | 0.140 |
Why?
| | Plasticizers | 1 | 2019 | 18 | 0.140 |
Why?
| | Brazil | 6 | 2017 | 179 | 0.140 |
Why?
| | Temporal Lobe | 1 | 2019 | 107 | 0.140 |
Why?
| | Indians, North American | 2 | 2021 | 598 | 0.140 |
Why?
| | Receptors, Immunologic | 3 | 2022 | 209 | 0.140 |
Why?
| | India | 3 | 2009 | 213 | 0.140 |
Why?
| | Aged, 80 and over | 10 | 2025 | 8346 | 0.140 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 2018 | 8 | 0.140 |
Why?
| | Metabolism | 1 | 2018 | 44 | 0.140 |
Why?
| | Clinical Trials as Topic | 2 | 2022 | 1062 | 0.140 |
Why?
| | Databases, Genetic | 4 | 2021 | 238 | 0.140 |
Why?
| | Metabolomics | 2 | 2024 | 733 | 0.140 |
Why?
| | Smad2 Protein | 1 | 2018 | 37 | 0.140 |
Why?
| | Eosinophilic Esophagitis | 1 | 2023 | 332 | 0.140 |
Why?
| | Brain | 2 | 2023 | 2969 | 0.140 |
Why?
| | Sex Characteristics | 3 | 2014 | 789 | 0.140 |
Why?
| | Hominidae | 1 | 2019 | 87 | 0.140 |
Why?
| | Family | 4 | 2012 | 684 | 0.140 |
Why?
| | Computer Communication Networks | 1 | 2018 | 32 | 0.140 |
Why?
| | Frontal Lobe | 1 | 2019 | 160 | 0.140 |
Why?
| | Exons | 3 | 2016 | 364 | 0.140 |
Why?
| | Telomerase | 2 | 2024 | 246 | 0.130 |
Why?
| | Lipopolysaccharide Receptors | 2 | 2010 | 88 | 0.130 |
Why?
| | Comorbidity | 1 | 2023 | 1662 | 0.130 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 440 | 0.130 |
Why?
| | Immunotherapy | 1 | 2022 | 667 | 0.130 |
Why?
| | Africa | 2 | 2020 | 119 | 0.130 |
Why?
| | Noncommunicable Diseases | 1 | 2017 | 21 | 0.130 |
Why?
| | Cross-Sectional Studies | 7 | 2025 | 5921 | 0.130 |
Why?
| | Quality Control | 4 | 2021 | 161 | 0.130 |
Why?
| | Organophosphates | 1 | 2019 | 179 | 0.130 |
Why?
| | Hyaluronoglucosaminidase | 1 | 2017 | 7 | 0.130 |
Why?
| | Information Storage and Retrieval | 1 | 2018 | 123 | 0.130 |
Why?
| | Molecular Epidemiology | 3 | 2013 | 74 | 0.130 |
Why?
| | Animals | 20 | 2023 | 38100 | 0.130 |
Why?
| | Rural Health | 1 | 1997 | 87 | 0.130 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2017 | 22 | 0.120 |
Why?
| | Schistosoma mansoni | 1 | 2017 | 41 | 0.120 |
Why?
| | Insulin Resistance | 1 | 2025 | 1244 | 0.120 |
Why?
| | Endemic Diseases | 1 | 2017 | 33 | 0.120 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 765 | 0.120 |
Why?
| | Sequence Analysis, DNA | 6 | 2018 | 778 | 0.120 |
Why?
| | Scavenger Receptors, Class B | 1 | 2016 | 14 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2020 | 554 | 0.120 |
Why?
| | DNA, Intergenic | 1 | 2016 | 26 | 0.120 |
Why?
| | Cyclooxygenase 1 | 2 | 2014 | 27 | 0.120 |
Why?
| | Schistosomiasis | 1 | 2017 | 50 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 484 | 0.120 |
Why?
| | Enhancer Elements, Genetic | 1 | 2017 | 191 | 0.120 |
Why?
| | Carotid Artery Diseases | 1 | 2016 | 70 | 0.120 |
Why?
| | White Matter | 1 | 2018 | 155 | 0.120 |
Why?
| | Erythropoiesis | 1 | 2016 | 57 | 0.120 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 668 | 0.120 |
Why?
| | Immune System Diseases | 1 | 2016 | 37 | 0.120 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 263 | 0.120 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2017 | 177 | 0.120 |
Why?
| | Lipoprotein(a) | 1 | 2016 | 69 | 0.120 |
Why?
| | Sexism | 1 | 2016 | 68 | 0.120 |
Why?
| | Kidney Transplantation | 2 | 2012 | 712 | 0.120 |
Why?
| | Myocardial Infarction | 2 | 2020 | 1211 | 0.120 |
Why?
| | Anthropometry | 2 | 2022 | 206 | 0.120 |
Why?
| | Severity of Illness Index | 5 | 2019 | 2933 | 0.110 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 273 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 2 | 2021 | 574 | 0.110 |
Why?
| | Lung Diseases, Interstitial | 1 | 2022 | 664 | 0.110 |
Why?
| | Cell Differentiation | 2 | 2021 | 2051 | 0.110 |
Why?
| | Genes, Modifier | 1 | 2015 | 2 | 0.110 |
Why?
| | Caveolin 2 | 1 | 2015 | 3 | 0.110 |
Why?
| | Factor VII | 1 | 2015 | 24 | 0.110 |
Why?
| | CpG Islands | 3 | 2023 | 171 | 0.110 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 175 | 0.110 |
Why?
| | Molecular Sequence Annotation | 3 | 2021 | 106 | 0.110 |
Why?
| | United Kingdom | 3 | 2021 | 358 | 0.110 |
Why?
| | Receptors, Interferon | 1 | 2015 | 60 | 0.110 |
Why?
| | Collagen | 2 | 2015 | 457 | 0.110 |
Why?
| | Schistosomiasis japonica | 1 | 2015 | 35 | 0.110 |
Why?
| | Interleukin-10 | 2 | 2017 | 310 | 0.110 |
Why?
| | Adenosine Triphosphatases | 1 | 2016 | 159 | 0.110 |
Why?
| | Mutation Rate | 1 | 2015 | 35 | 0.110 |
Why?
| | Minority Groups | 1 | 2017 | 285 | 0.110 |
Why?
| | Scleroderma, Systemic | 1 | 2016 | 123 | 0.110 |
Why?
| | Mutant Chimeric Proteins | 1 | 2014 | 6 | 0.110 |
Why?
| | KCNQ1 Potassium Channel | 1 | 2014 | 8 | 0.110 |
Why?
| | Menopause | 2 | 2023 | 326 | 0.110 |
Why?
| | HLA-B27 Antigen | 1 | 2014 | 16 | 0.110 |
Why?
| | HMGA2 Protein | 1 | 2014 | 10 | 0.110 |
Why?
| | Chromosome Disorders | 1 | 2014 | 47 | 0.110 |
Why?
| | Hypertension | 2 | 2022 | 1276 | 0.110 |
Why?
| | Machine Learning | 3 | 2025 | 587 | 0.110 |
Why?
| | Transcription Factor 7-Like 2 Protein | 1 | 2014 | 26 | 0.110 |
Why?
| | Cells, Cultured | 2 | 2021 | 4151 | 0.110 |
Why?
| | Rhinitis, Allergic | 1 | 2014 | 42 | 0.100 |
Why?
| | Family Health | 4 | 2011 | 191 | 0.100 |
Why?
| | Tobacco Use Disorder | 2 | 2013 | 217 | 0.100 |
Why?
| | Transmembrane Activator and CAML Interactor Protein | 1 | 2013 | 4 | 0.100 |
Why?
| | Cystic Fibrosis | 2 | 2015 | 1163 | 0.100 |
Why?
| | beta-Defensins | 1 | 2013 | 22 | 0.100 |
Why?
| | Family Practice | 1 | 1997 | 407 | 0.100 |
Why?
| | Body Mass Index | 5 | 2022 | 2447 | 0.100 |
Why?
| | Vital Capacity | 1 | 2014 | 292 | 0.100 |
Why?
| | Exercise | 1 | 2025 | 2203 | 0.100 |
Why?
| | Obesity | 2 | 2022 | 3118 | 0.100 |
Why?
| | Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 1993 | 14 | 0.100 |
Why?
| | Kv Channel-Interacting Proteins | 1 | 2013 | 2 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2017 | 584 | 0.100 |
Why?
| | Professional Impairment | 1 | 1993 | 3 | 0.100 |
Why?
| | Chemokine CXCL12 | 1 | 2013 | 86 | 0.100 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2011 | 80 | 0.100 |
Why?
| | Virginia | 2 | 2005 | 57 | 0.100 |
Why?
| | Longitudinal Studies | 5 | 2021 | 2967 | 0.100 |
Why?
| | Dentists | 1 | 1993 | 21 | 0.100 |
Why?
| | Pseudomonas aeruginosa | 2 | 2015 | 395 | 0.100 |
Why?
| | HEK293 Cells | 3 | 2021 | 741 | 0.100 |
Why?
| | Genetic Markers | 5 | 2016 | 338 | 0.090 |
Why?
| | Stroke | 1 | 2022 | 1271 | 0.090 |
Why?
| | Skin Tests | 4 | 2017 | 94 | 0.090 |
Why?
| | K562 Cells | 2 | 2024 | 92 | 0.090 |
Why?
| | Principal Component Analysis | 2 | 2010 | 194 | 0.090 |
Why?
| | Microbiota | 1 | 2020 | 730 | 0.090 |
Why?
| | Hepatocyte Nuclear Factor 3-alpha | 1 | 2012 | 9 | 0.090 |
Why?
| | Ankyrins | 1 | 2012 | 11 | 0.090 |
Why?
| | Parents | 3 | 2007 | 1404 | 0.090 |
Why?
| | Kallikreins | 1 | 2012 | 26 | 0.090 |
Why?
| | Duffy Blood-Group System | 2 | 2011 | 5 | 0.090 |
Why?
| | Critical Care | 1 | 2019 | 702 | 0.090 |
Why?
| | Nuclear Proteins | 1 | 2017 | 740 | 0.090 |
Why?
| | Phylogeny | 1 | 2016 | 917 | 0.090 |
Why?
| | Fatty Acids | 1 | 2015 | 457 | 0.090 |
Why?
| | Respiratory Sounds | 1 | 2012 | 103 | 0.090 |
Why?
| | Triglycerides | 3 | 2015 | 520 | 0.090 |
Why?
| | Hepatitis B | 1 | 1993 | 66 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 1997 | 562 | 0.090 |
Why?
| | Leukocyte Count | 2 | 2011 | 318 | 0.090 |
Why?
| | Mitochondria | 1 | 2018 | 992 | 0.090 |
Why?
| | Dioxygenases | 2 | 2023 | 34 | 0.090 |
Why?
| | Prostate-Specific Antigen | 1 | 2012 | 161 | 0.090 |
Why?
| | Steroids | 1 | 2012 | 160 | 0.090 |
Why?
| | Heterozygote | 3 | 2021 | 314 | 0.080 |
Why?
| | Insulin | 4 | 2022 | 2516 | 0.080 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2011 | 14 | 0.080 |
Why?
| | Microtubule-Associated Proteins | 1 | 2012 | 194 | 0.080 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2011 | 36 | 0.080 |
Why?
| | Aquaporin 5 | 1 | 2010 | 3 | 0.080 |
Why?
| | Patients | 1 | 1993 | 183 | 0.080 |
Why?
| | Gene Expression Profiling | 2 | 2025 | 1777 | 0.080 |
Why?
| | Reproducibility of Results | 6 | 2021 | 3416 | 0.080 |
Why?
| | Disease Progression | 5 | 2019 | 2865 | 0.080 |
Why?
| | Heredity | 2 | 2021 | 13 | 0.080 |
Why?
| | Chromosomes | 1 | 2011 | 106 | 0.080 |
Why?
| | Mice | 11 | 2023 | 18357 | 0.080 |
Why?
| | Cockroaches | 1 | 2010 | 23 | 0.080 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2010 | 28 | 0.080 |
Why?
| | Recombination, Genetic | 1 | 2011 | 205 | 0.080 |
Why?
| | Death Domain Receptor Signaling Adaptor Proteins | 1 | 2009 | 2 | 0.080 |
Why?
| | Curriculum | 1 | 1997 | 1074 | 0.080 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 1 | 2010 | 36 | 0.080 |
Why?
| | Eosinophils | 2 | 2025 | 316 | 0.080 |
Why?
| | Lectins | 1 | 2010 | 44 | 0.080 |
Why?
| | Incidence | 4 | 2019 | 2933 | 0.080 |
Why?
| | Myocardial Ischemia | 1 | 2011 | 285 | 0.070 |
Why?
| | Nuclear Family | 2 | 2007 | 50 | 0.070 |
Why?
| | Isoenzymes | 1 | 2010 | 295 | 0.070 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2009 | 64 | 0.070 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2009 | 76 | 0.070 |
Why?
| | Interviews as Topic | 2 | 2006 | 911 | 0.070 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2009 | 15 | 0.070 |
Why?
| | Chromosomes, Human | 1 | 2009 | 44 | 0.070 |
Why?
| | Tryptophan | 1 | 2010 | 182 | 0.070 |
Why?
| | Interferon-alpha | 1 | 2010 | 193 | 0.070 |
Why?
| | Arginine | 1 | 2010 | 264 | 0.070 |
Why?
| | Caribbean Region | 4 | 2011 | 29 | 0.070 |
Why?
| | Confidence Intervals | 2 | 2014 | 330 | 0.070 |
Why?
| | Receptors, Leptin | 1 | 2009 | 25 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3915 | 0.070 |
Why?
| | Renal Dialysis | 1 | 1993 | 466 | 0.070 |
Why?
| | Graft Rejection | 1 | 2012 | 521 | 0.070 |
Why?
| | Agammaglobulinemia | 1 | 1989 | 36 | 0.070 |
Why?
| | Regression Analysis | 3 | 2025 | 1001 | 0.070 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2009 | 55 | 0.070 |
Why?
| | Nephrotic Syndrome | 1 | 1989 | 43 | 0.070 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2022 | 376 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2017 | 1101 | 0.070 |
Why?
| | Proto-Oncogene Proteins | 2 | 2023 | 625 | 0.070 |
Why?
| | Genotyping Techniques | 2 | 2019 | 71 | 0.070 |
Why?
| | Thromboxane B2 | 3 | 2018 | 23 | 0.070 |
Why?
| | Proteoglycans | 1 | 2009 | 112 | 0.070 |
Why?
| | Cholesterol | 2 | 2015 | 408 | 0.070 |
Why?
| | Siblings | 2 | 2011 | 196 | 0.070 |
Why?
| | Alcoholism | 3 | 2005 | 826 | 0.070 |
Why?
| | Chromosomes, Human, Pair 17 | 3 | 2019 | 54 | 0.070 |
Why?
| | Polymerase Chain Reaction | 2 | 2012 | 1043 | 0.070 |
Why?
| | Research Design | 2 | 2019 | 1139 | 0.070 |
Why?
| | Myosin-Light-Chain Kinase | 1 | 2007 | 19 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 838 | 0.060 |
Why?
| | British Columbia | 3 | 1997 | 25 | 0.060 |
Why?
| | Age of Onset | 3 | 2013 | 557 | 0.060 |
Why?
| | Inheritance Patterns | 1 | 2006 | 45 | 0.060 |
Why?
| | Cognition | 1 | 2015 | 1271 | 0.060 |
Why?
| | Antigens, CD | 1 | 2010 | 558 | 0.060 |
Why?
| | Databases, Factual | 1 | 2012 | 1491 | 0.060 |
Why?
| | Thrombophilia | 1 | 2007 | 89 | 0.060 |
Why?
| | Deoxyribonuclease HindIII | 1 | 2006 | 2 | 0.060 |
Why?
| | Infant, Newborn | 6 | 2012 | 6464 | 0.060 |
Why?
| | alpha-Linolenic Acid | 2 | 2017 | 8 | 0.060 |
Why?
| | Meta-Analysis as Topic | 3 | 2012 | 173 | 0.060 |
Why?
| | Adenosine Diphosphate | 2 | 2017 | 83 | 0.060 |
Why?
| | Europe | 2 | 2020 | 421 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2022 | 442 | 0.060 |
Why?
| | Chromosomes, Human, Pair 4 | 2 | 2019 | 25 | 0.060 |
Why?
| | Platelet Count | 2 | 2016 | 94 | 0.060 |
Why?
| | Registries | 1 | 2014 | 2410 | 0.060 |
Why?
| | DNA Mutational Analysis | 2 | 2020 | 410 | 0.060 |
Why?
| | Prospective Studies | 5 | 2020 | 8075 | 0.060 |
Why?
| | Epinephrine | 2 | 2017 | 158 | 0.060 |
Why?
| | Glucose | 2 | 2022 | 1048 | 0.060 |
Why?
| | Ozone | 1 | 2006 | 116 | 0.060 |
Why?
| | Transfection | 3 | 2016 | 927 | 0.050 |
Why?
| | Receptors, Prostaglandin | 1 | 2004 | 21 | 0.050 |
Why?
| | Complement C3 | 1 | 2006 | 187 | 0.050 |
Why?
| | Mucins | 1 | 2005 | 75 | 0.050 |
Why?
| | ABO Blood-Group System | 1 | 2025 | 58 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2005 | 163 | 0.050 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2024 | 26 | 0.050 |
Why?
| | Janus Kinase 2 | 1 | 2024 | 29 | 0.050 |
Why?
| | Mites | 1 | 2004 | 8 | 0.050 |
Why?
| | Loss of Heterozygosity | 1 | 2024 | 52 | 0.050 |
Why?
| | National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2024 | 25 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2016 | 1957 | 0.050 |
Why?
| | Gene Targeting | 2 | 2020 | 81 | 0.050 |
Why?
| | Eye Proteins | 2 | 2021 | 92 | 0.050 |
Why?
| | Kidney | 2 | 2023 | 1498 | 0.050 |
Why?
| | Matched-Pair Analysis | 1 | 2003 | 37 | 0.050 |
Why?
| | Chromosomes, Human, Pair 14 | 2 | 2014 | 23 | 0.050 |
Why?
| | Adult Children | 1 | 2003 | 27 | 0.050 |
Why?
| | Time | 1 | 2003 | 84 | 0.050 |
Why?
| | Interleukin-6 | 2 | 2024 | 779 | 0.050 |
Why?
| | Epigenomics | 1 | 2024 | 117 | 0.050 |
Why?
| | Receptors, Complement | 1 | 2004 | 123 | 0.050 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2024 | 104 | 0.050 |
Why?
| | Guanine Nucleotide Dissociation Inhibitors | 1 | 2023 | 2 | 0.050 |
Why?
| | Societies, Medical | 2 | 2019 | 900 | 0.050 |
Why?
| | Genes | 1 | 2003 | 228 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2014 | 4569 | 0.050 |
Why?
| | Environment | 2 | 2010 | 293 | 0.050 |
Why?
| | Diabetic Retinopathy | 1 | 2006 | 209 | 0.050 |
Why?
| | Sex Factors | 3 | 2014 | 2110 | 0.050 |
Why?
| | Sulfites | 1 | 2023 | 8 | 0.050 |
Why?
| | Eosinophilia | 2 | 2023 | 224 | 0.050 |
Why?
| | Aminopeptidases | 1 | 2023 | 20 | 0.050 |
Why?
| | Disease Susceptibility | 3 | 2014 | 344 | 0.050 |
Why?
| | Membrane Glycoproteins | 2 | 2005 | 499 | 0.050 |
Why?
| | Cell Line | 3 | 2015 | 2823 | 0.050 |
Why?
| | Genes, Reporter | 2 | 2015 | 277 | 0.050 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2022 | 15 | 0.050 |
Why?
| | Pruritus | 1 | 2023 | 60 | 0.050 |
Why?
| | Cooperative Behavior | 1 | 2005 | 463 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2016 | 2805 | 0.050 |
Why?
| | CRISPR-Cas Systems | 1 | 2024 | 166 | 0.050 |
Why?
| | Frail Elderly | 1 | 2023 | 136 | 0.050 |
Why?
| | Syndrome | 1 | 2023 | 381 | 0.050 |
Why?
| | Fruit | 1 | 2023 | 146 | 0.050 |
Why?
| | Electroencephalography | 1 | 2005 | 563 | 0.050 |
Why?
| | Vegetables | 1 | 2023 | 161 | 0.050 |
Why?
| | Colorado | 2 | 2024 | 4556 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2023 | 279 | 0.040 |
Why?
| | Risk Assessment | 2 | 2025 | 3752 | 0.040 |
Why?
| | Chromatin | 1 | 2025 | 553 | 0.040 |
Why?
| | Age Factors | 3 | 2003 | 3346 | 0.040 |
Why?
| | RGS Proteins | 1 | 2021 | 17 | 0.040 |
Why?
| | Internationality | 2 | 2013 | 156 | 0.040 |
Why?
| | Subcutaneous Tissue | 1 | 2021 | 26 | 0.040 |
Why?
| | INDEL Mutation | 1 | 2021 | 22 | 0.040 |
Why?
| | Antigens, Protozoan | 1 | 2001 | 32 | 0.040 |
Why?
| | Colombia | 2 | 2013 | 42 | 0.040 |
Why?
| | Antibodies, Protozoan | 1 | 2001 | 41 | 0.040 |
Why?
| | Postmenopause | 1 | 2023 | 394 | 0.040 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2021 | 32 | 0.040 |
Why?
| | alpha Karyopherins | 1 | 2020 | 11 | 0.040 |
Why?
| | Receptors, LDL | 1 | 2020 | 53 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2021 | 118 | 0.040 |
Why?
| | Antibodies, Heterophile | 1 | 2000 | 12 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2021 | 92 | 0.040 |
Why?
| | Lymphocytosis | 1 | 2000 | 12 | 0.040 |
Why?
| | Cricetinae | 1 | 2001 | 305 | 0.040 |
Why?
| | Population Density | 1 | 2021 | 89 | 0.040 |
Why?
| | Tripartite Motif Proteins | 1 | 2020 | 39 | 0.040 |
Why?
| | GTP-Binding Proteins | 1 | 2021 | 153 | 0.040 |
Why?
| | Sample Size | 1 | 2021 | 121 | 0.040 |
Why?
| | Lod Score | 3 | 2009 | 62 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2021 | 83 | 0.040 |
Why?
| | Sepsis | 1 | 2007 | 664 | 0.040 |
Why?
| | Cell Self Renewal | 1 | 2020 | 52 | 0.040 |
Why?
| | Eating | 1 | 2023 | 387 | 0.040 |
Why?
| | Prognosis | 2 | 2021 | 4329 | 0.040 |
Why?
| | Names | 1 | 2000 | 15 | 0.040 |
Why?
| | Pneumonia | 1 | 2006 | 636 | 0.040 |
Why?
| | Respiratory Function Tests | 2 | 2013 | 544 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2006 | 835 | 0.040 |
Why?
| | Lens, Crystalline | 1 | 2001 | 136 | 0.040 |
Why?
| | Gene Editing | 1 | 2021 | 89 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2020 | 27 | 0.040 |
Why?
| | Mutagenesis | 1 | 2021 | 194 | 0.040 |
Why?
| | Mucin-5B | 1 | 2022 | 234 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 202 | 0.040 |
Why?
| | A549 Cells | 1 | 2019 | 75 | 0.040 |
Why?
| | North America | 2 | 2011 | 303 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2023 | 429 | 0.040 |
Why?
| | Fibrinolysis | 1 | 2021 | 164 | 0.040 |
Why?
| | Time Factors | 3 | 2019 | 7133 | 0.040 |
Why?
| | Body Weight | 1 | 2003 | 972 | 0.040 |
Why?
| | Siberia | 1 | 2019 | 7 | 0.040 |
Why?
| | Emigration and Immigration | 1 | 2000 | 66 | 0.040 |
Why?
| | Information Dissemination | 1 | 2021 | 224 | 0.040 |
Why?
| | Up-Regulation | 2 | 2016 | 848 | 0.040 |
Why?
| | Flame Ionization | 1 | 2019 | 2 | 0.040 |
Why?
| | Cloud Computing | 1 | 2019 | 6 | 0.040 |
Why?
| | Linear Models | 2 | 2017 | 849 | 0.040 |
Why?
| | Recombinases | 1 | 2019 | 10 | 0.040 |
Why?
| | Event-Related Potentials, P300 | 1 | 1999 | 17 | 0.040 |
Why?
| | Waist-Hip Ratio | 1 | 2018 | 37 | 0.040 |
Why?
| | Monoamine Oxidase | 1 | 1999 | 27 | 0.040 |
Why?
| | Cataract | 1 | 2001 | 238 | 0.040 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 2019 | 39 | 0.040 |
Why?
| | Antibodies, Viral | 2 | 2000 | 674 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2014 | 1330 | 0.040 |
Why?
| | Limit of Detection | 1 | 2019 | 92 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2022 | 630 | 0.030 |
Why?
| | RNA Splicing Factors | 1 | 2019 | 66 | 0.030 |
Why?
| | Calibration | 1 | 2019 | 152 | 0.030 |
Why?
| | Reference Standards | 1 | 2019 | 177 | 0.030 |
Why?
| | Prevalence | 2 | 2016 | 2874 | 0.030 |
Why?
| | Organ Size | 1 | 2019 | 461 | 0.030 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2018 | 10 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2019 | 571 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 2019 | 2525 | 0.030 |
Why?
| | Virus Diseases | 1 | 2000 | 216 | 0.030 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2017 | 25 | 0.030 |
Why?
| | Skin | 1 | 2023 | 754 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2024 | 877 | 0.030 |
Why?
| | Double-Blind Method | 2 | 2020 | 2064 | 0.030 |
Why?
| | Histone Code | 1 | 2017 | 39 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 457 | 0.030 |
Why?
| | Rubella Vaccine | 1 | 1997 | 7 | 0.030 |
Why?
| | Program Evaluation | 1 | 2021 | 943 | 0.030 |
Why?
| | HIV Infections | 1 | 1993 | 3195 | 0.030 |
Why?
| | Adipocytes | 1 | 2018 | 223 | 0.030 |
Why?
| | Rubella | 1 | 1997 | 23 | 0.030 |
Why?
| | Apolipoprotein E2 | 1 | 2016 | 3 | 0.030 |
Why?
| | Apolipoprotein B-100 | 1 | 2016 | 13 | 0.030 |
Why?
| | Selection, Genetic | 1 | 2019 | 263 | 0.030 |
Why?
| | Interleukin-33 | 1 | 2017 | 45 | 0.030 |
Why?
| | GPI-Linked Proteins | 1 | 2017 | 81 | 0.030 |
Why?
| | Preceptorship | 1 | 1997 | 63 | 0.030 |
Why?
| | Demography | 1 | 2017 | 282 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2018 | 501 | 0.030 |
Why?
| | Workflow | 1 | 2018 | 183 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2005 | 1997 | 0.030 |
Why?
| | Denmark | 1 | 2016 | 51 | 0.030 |
Why?
| | Data Accuracy | 1 | 2017 | 65 | 0.030 |
Why?
| | Mean Platelet Volume | 1 | 2016 | 3 | 0.030 |
Why?
| | Allelic Imbalance | 1 | 2016 | 9 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2019 | 248 | 0.030 |
Why?
| | Erythrocyte Indices | 1 | 2016 | 33 | 0.030 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2016 | 75 | 0.030 |
Why?
| | Massachusetts | 1 | 2017 | 180 | 0.030 |
Why?
| | Neoplasms | 1 | 2012 | 2913 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2016 | 55 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5428 | 0.030 |
Why?
| | Hematocrit | 1 | 2016 | 108 | 0.030 |
Why?
| | DNA | 1 | 2023 | 1437 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 104 | 0.030 |
Why?
| | China | 1 | 2017 | 273 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1897 | 0.030 |
Why?
| | Stearic Acids | 1 | 2015 | 15 | 0.030 |
Why?
| | Sarcoglycans | 1 | 2015 | 5 | 0.030 |
Why?
| | Bias | 1 | 2016 | 197 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 302 | 0.030 |
Why?
| | Lung Volume Measurements | 1 | 2015 | 46 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1547 | 0.030 |
Why?
| | Computed Tomography Angiography | 1 | 2016 | 146 | 0.030 |
Why?
| | Protein Transport | 1 | 2017 | 442 | 0.030 |
Why?
| | STAT1 Transcription Factor | 1 | 2015 | 66 | 0.030 |
Why?
| | Vascular Calcification | 1 | 2016 | 110 | 0.030 |
Why?
| | HTLV-I Infections | 1 | 1995 | 29 | 0.030 |
Why?
| | Glucose-6-Phosphatase | 1 | 2015 | 32 | 0.030 |
Why?
| | Social Class | 1 | 2017 | 264 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 337 | 0.030 |
Why?
| | Nutritional Status | 1 | 2017 | 353 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2017 | 337 | 0.030 |
Why?
| | Mice, Knockout | 3 | 2009 | 3130 | 0.030 |
Why?
| | Coronary Angiography | 1 | 2016 | 328 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2014 | 36 | 0.030 |
Why?
| | Potassium Channels | 1 | 2015 | 148 | 0.030 |
Why?
| | Pneumothorax | 1 | 2014 | 52 | 0.030 |
Why?
| | Host-Parasite Interactions | 1 | 2015 | 110 | 0.030 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2015 | 88 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2028 | 0.030 |
Why?
| | Myosin Heavy Chains | 1 | 2015 | 183 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 561 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2019 | 910 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2018 | 441 | 0.030 |
Why?
| | Health Policy | 1 | 2017 | 400 | 0.020 |
Why?
| | Hemoglobins | 1 | 2016 | 386 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2022 | 1149 | 0.020 |
Why?
| | Diet, Western | 1 | 2014 | 88 | 0.020 |
Why?
| | alpha 1-Antitrypsin | 1 | 2014 | 104 | 0.020 |
Why?
| | Deferoxamine | 1 | 1993 | 27 | 0.020 |
Why?
| | Jamaica | 1 | 2013 | 9 | 0.020 |
Why?
| | Cotinine | 1 | 2013 | 77 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2014 | 175 | 0.020 |
Why?
| | District of Columbia | 1 | 2013 | 38 | 0.020 |
Why?
| | Societies, Dental | 1 | 1993 | 2 | 0.020 |
Why?
| | Aluminum | 1 | 1993 | 43 | 0.020 |
Why?
| | Gene Order | 1 | 2012 | 29 | 0.020 |
Why?
| | Educational Status | 1 | 2015 | 470 | 0.020 |
Why?
| | New York | 1 | 2013 | 128 | 0.020 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2012 | 20 | 0.020 |
Why?
| | Dynactin Complex | 1 | 2012 | 5 | 0.020 |
Why?
| | Parathyroid Hormone | 1 | 1993 | 114 | 0.020 |
Why?
| | Immunity, Mucosal | 1 | 2013 | 98 | 0.020 |
Why?
| | Organizational Policy | 1 | 1993 | 78 | 0.020 |
Why?
| | Untranslated Regions | 1 | 2012 | 3 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2009 | 6084 | 0.020 |
Why?
| | Adolescent Development | 1 | 2012 | 72 | 0.020 |
Why?
| | Statistics, Nonparametric | 2 | 2005 | 428 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 971 | 0.020 |
Why?
| | Wales | 1 | 2011 | 26 | 0.020 |
Why?
| | Chemokine CXCL2 | 1 | 2011 | 41 | 0.020 |
Why?
| | England | 1 | 2011 | 110 | 0.020 |
Why?
| | Epidemiologic Methods | 1 | 2011 | 91 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2014 | 507 | 0.020 |
Why?
| | Biological Evolution | 1 | 2015 | 468 | 0.020 |
Why?
| | Canada | 1 | 2012 | 432 | 0.020 |
Why?
| | X Chromosome Inactivation | 1 | 2011 | 25 | 0.020 |
Why?
| | Eicosapentaenoic Acid | 1 | 2011 | 37 | 0.020 |
Why?
| | Luciferases | 1 | 2011 | 154 | 0.020 |
Why?
| | Microsatellite Repeats | 2 | 2003 | 157 | 0.020 |
Why?
| | Costa Rica | 1 | 2010 | 18 | 0.020 |
Why?
| | Pulmonary Fibrosis | 1 | 2014 | 395 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1810 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2015 | 729 | 0.020 |
Why?
| | Salmeterol Xinafoate | 1 | 2010 | 20 | 0.020 |
Why?
| | Overweight | 1 | 2015 | 614 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 404 | 0.020 |
Why?
| | Artifacts | 1 | 2011 | 143 | 0.020 |
Why?
| | Iron | 1 | 1993 | 359 | 0.020 |
Why?
| | Codon, Nonsense | 1 | 2010 | 45 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 388 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2011 | 135 | 0.020 |
Why?
| | Bone and Bones | 1 | 1993 | 318 | 0.020 |
Why?
| | Introns | 1 | 2011 | 256 | 0.020 |
Why?
| | Albuterol | 1 | 2010 | 76 | 0.020 |
Why?
| | Markov Chains | 1 | 2010 | 132 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1300 | 0.020 |
Why?
| | Kainic Acid | 1 | 2009 | 33 | 0.020 |
Why?
| | Nicotine | 1 | 2012 | 331 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2010 | 247 | 0.020 |
Why?
| | Biopsy | 1 | 1993 | 1082 | 0.020 |
Why?
| | Plasmids | 1 | 2010 | 373 | 0.020 |
Why?
| | Waist Circumference | 1 | 2010 | 143 | 0.020 |
Why?
| | Excitatory Amino Acid Agonists | 1 | 2009 | 42 | 0.020 |
Why?
| | Urban Population | 1 | 2012 | 494 | 0.020 |
Why?
| | Acute Disease | 1 | 2012 | 1036 | 0.020 |
Why?
| | DNA Replication | 1 | 2011 | 249 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2009 | 162 | 0.020 |
Why?
| | Bronchodilator Agents | 1 | 2010 | 187 | 0.020 |
Why?
| | Disease | 1 | 2009 | 96 | 0.020 |
Why?
| | Hospitals | 1 | 1993 | 733 | 0.020 |
Why?
| | Spirometry | 1 | 2009 | 233 | 0.020 |
Why?
| | Korea | 1 | 2007 | 18 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 2000 | 0.020 |
Why?
| | beta-Thromboglobulin | 1 | 2007 | 3 | 0.020 |
Why?
| | Quality of Life | 1 | 2019 | 3210 | 0.020 |
Why?
| | Binding Sites | 1 | 2010 | 1311 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2010 | 500 | 0.020 |
Why?
| | Drug Resistance | 1 | 2007 | 145 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1736 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2009 | 560 | 0.010 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2006 | 33 | 0.010 |
Why?
| | Genetic Testing | 2 | 1999 | 483 | 0.010 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2005 | 43 | 0.010 |
Why?
| | False Positive Reactions | 1 | 2005 | 123 | 0.010 |
Why?
| | Hepatitis A Antibodies | 1 | 2005 | 3 | 0.010 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2005 | 28 | 0.010 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2005 | 43 | 0.010 |
Why?
| | Hepatitis A | 1 | 2005 | 25 | 0.010 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2004 | 26 | 0.010 |
Why?
| | Receptors, Virus | 1 | 2005 | 95 | 0.010 |
Why?
| | Seroepidemiologic Studies | 1 | 2005 | 171 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2009 | 1723 | 0.010 |
Why?
| | Antigens, Dermatophagoides | 1 | 2004 | 10 | 0.010 |
Why?
| | U937 Cells | 1 | 2004 | 28 | 0.010 |
Why?
| | Chromosomes, Human, Pair 20 | 1 | 2004 | 17 | 0.010 |
Why?
| | Gene Deletion | 1 | 2006 | 392 | 0.010 |
Why?
| | NIH 3T3 Cells | 1 | 2004 | 146 | 0.010 |
Why?
| | Receptor, Anaphylatoxin C5a | 1 | 2004 | 35 | 0.010 |
Why?
| | Germany | 1 | 2004 | 138 | 0.010 |
Why?
| | 3' Untranslated Regions | 1 | 2004 | 149 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2018 | 11793 | 0.010 |
Why?
| | Pulmonary Alveoli | 1 | 2006 | 387 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2006 | 1261 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2007 | 379 | 0.010 |
Why?
| | Kinetics | 1 | 2006 | 1568 | 0.010 |
Why?
| | Aquaporins | 1 | 2001 | 8 | 0.010 |
Why?
| | Chimera | 1 | 2001 | 61 | 0.010 |
Why?
| | Osmosis | 1 | 2001 | 22 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 2001 | 123 | 0.010 |
Why?
| | Optics and Photonics | 1 | 2001 | 38 | 0.010 |
Why?
| | Permeability | 1 | 2001 | 169 | 0.010 |
Why?
| | Lasers | 1 | 2001 | 127 | 0.010 |
Why?
| | Western Australia | 1 | 2001 | 8 | 0.010 |
Why?
| | HIV-2 | 1 | 2000 | 18 | 0.010 |
Why?
| | Cost Control | 1 | 2000 | 38 | 0.010 |
Why?
| | Herpesvirus 6, Human | 1 | 2000 | 14 | 0.010 |
Why?
| | Toxoplasma | 1 | 2000 | 49 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2004 | 2883 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 2000 | 172 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 2000 | 168 | 0.010 |
Why?
| | Expert Testimony | 1 | 1999 | 43 | 0.010 |
Why?
| | Immunoglobulin M | 1 | 2000 | 265 | 0.010 |
Why?
| | Observer Variation | 1 | 1999 | 357 | 0.010 |
Why?
| | Lymphocytes | 1 | 2000 | 376 | 0.010 |
Why?
| | Water | 1 | 2001 | 447 | 0.010 |
Why?
| | Rats | 1 | 2006 | 5585 | 0.010 |
Why?
| | Rubella virus | 1 | 1997 | 7 | 0.010 |
Why?
| | Paresthesia | 1 | 1997 | 14 | 0.010 |
Why?
| | Arthralgia | 1 | 1997 | 61 | 0.010 |
Why?
| | Muscular Diseases | 1 | 1997 | 109 | 0.010 |
Why?
| | Vaccines, Attenuated | 1 | 1997 | 129 | 0.010 |
Why?
| | Arthritis | 1 | 1997 | 96 | 0.010 |
Why?
| | HIV-1 | 1 | 2000 | 908 | 0.010 |
Why?
| | Postpartum Period | 1 | 1997 | 373 | 0.010 |
Why?
| | Pain | 1 | 1997 | 791 | 0.010 |
Why?
| | Physicians | 1 | 1999 | 956 | 0.010 |
Why?
| | Vaccination | 1 | 1997 | 1428 | 0.000 |
Why?
|
|
Mathias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|